Key result
Intraoperative administration of salbutamol/budesonide significantly reduced the incidence of postoperative myocardial injury compared to control (22% vs 38%).
Why the study?
To investigate whether the administration of salbutamol/budesonide reduces the incidence of myocardial injury in thoracic surgery.
Does intraoperative salbutamol/budesonide reduce the incidence of myocardial injury in patients over 45 at high risk for cardiovascular complications undergoing lobectomy?
RCT (n=298)
Does intraoperative salbutamol/budesonide reduce the incidence of myocardial injury in patients over 45 at high risk for cardiovascular complications undergoing lobectomy?
Absolute Event Rate: 22% vs 38%
Intraoperative administration of salbutamol/budesonide significantly reduces the incidence of myocardial injury and improves lung function in high-risk patients undergoing lobectomy.
Lowers myocardial injury risk with intraoperative salbutamol/budesonide in high-risk lobectomy; extends perioperative cardioprotection evidence in thoracic surgery.
Purpose: This study aims to investigate whether the administration of salbutamol/budesonide reduced the incidence of myocardial injury in thoracic surgery. Methods: The randomized controlled trial included 298 patients over 45 and at high-risk for cardiovascular complications after lobectomy. Patients in the experimental group were treated with salbutamol/budesonide after anesthesia induction with fiberoptic bronchoscope. The primary outcome was the incidence rates of myocardial injury, assessed before and three days after the operation. The secondary outcome was respiratory function at each time point during the operation, including lung compliance and arterial partial pressure of oxygen, postoperative pulmonary and cardiovascular complications, hospital stay, pain score, and analgesic dosage. Results: In the control group, the incidence of myocardial injury was 57/150 (38%), while that in the experimental group was 33/148 (22%); compared between the two groups, the difference in the incidence of myocardial injury was statistically significant. The dynamic compliance and static compliance at half an hour after the start of surgery in the experimental group were significantly improved. Before leaving the operating room, the difference in arterial oxygen partial pressure between the two groups was statistically significant. Conclusion: Intraoperative administration of salbutamol/budesonide reduced the incidence of myocardial injury after thoracic surgery, improved lung function, and reduced the incidence of postoperative pulmonary complications.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2023) conducted an RCT in High-risk for cardiovascular complications after lobectomy (n=298). Salbutamol/budesonide vs. Control was evaluated on Incidence rates of myocardial injury, assessed before and three days after the operation. Intraoperative administration of salbutamol/budesonide significantly reduced the incidence of postoperative myocardial injury compared to control (22% vs 38%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: